Telix Pharmaceuticals
(ASX:TLX) has today announced the completion of its acquisition of Atlab Pharma.
As part of the $10 million takeover Telix has also renegotiated Atlab's material background intellectual property licenses
The company says the acquisition supports potential expansion for Telix's treatment TLX591.
Atlab also possesses rights to an extensive clinical data set in about 200 patients that well help with the further development of TLX591.
Shares in Telix
(ASX:TLX) is trading 1.72 per cent higher to 89 cents.
